Skip to main content

Table 3 Univariable and multivariable analyses to assess variables independently associated with favorable neurological outcome at 3 months

From: Acute kidney injury after cardiac arrest

Variable Favorable neurological outcome (n = 81) Poor neurological outcome (n = 118) Univariate analysis Multivariate analysis
Odds ratio (95% CI) P -value Odds ratio (95% CI) P -value
Acute kidney injury, n (%) 29 (36) 56 (47) 0.664 (0.368, 1.197] 0.17   
Age, years 58 (49 to 71) 66 (53 to 77) 0.981 (0.963, 0.999) 0.04 0.963 (0.937, 0.990) 0.007
Weight, kgs 77 (70 to 90) 75 (65 to 85) 1.012 (0.993, 1.031) 0.24   
Male, n (%) 63 (78) 71 (60) 2.622 (1.341, 5.126) 0.005   
Witnessed CA 70 (87) 78 (66) 2.695 (1.283, 5.664) 0.009   
Bystander CPR, n (%) 60 (74) 52 (44) 2.823 (1.526, 5.224) 0.001 3.682 (1.522, 8.908) 0.004
Time to ROSC, min 13 (7 to 21) 18 (10 to 27) 0.980 (0.958, 1.002) 0.07 1.085 (1.009, 1.167) 0.03
Epinephrine, mg 3 (1 to 5) 5 (3 to 7) 0.846 (0.766, 0.935) 0.001 0.594 (0.439, 0.804) 0.001
Out- of-hospital CA 45 (56) 76 (64) 0.836 (0.465, 1.503) 0.55   
Non-cardiac origin CA 18 (22) 51 (43) 0.297 (0.150, 0.586) <0.001   
VF/VT, n (%) 52 (64) 29 (25) 3.858 (2.925, 4.710) <0.001 3.797 (2.922, 4.539) <0.001
Infection during ICU stay, n (%) 49 (60) 74 (63) 1.165 (0.640, 2.121) 0.63   
IABP during ICU stay, n (%) 6 (7) 9 (8) 1.137 (0.388, 3.334) 0.82   
ECMO during ICU stay, n (%) 10 (12) 12 (10) 1.193 (0.483, 2.943) 0.70   
Shock during ICU stay, n (%) 36 (44) 67 (57) 0.531 (0.296, 0.950) 0.03 0.433 (0.187, 0.998) 0.049
Corticosteroid therapy, n (%) 10 (12) 19 (16) 0.720 (0.309, 1.677) 0.45   
Chronic heart failure, n (%) 20 (24) 37 (31) 0.502 (0.255, 0.989) 0.05   
Hypertension, n (%) 28 (35) 49 (42) 0.786 (0.433, 1.426) 0.43   
Coronary artery disease, n (%) 37 (46) 49 (42) 1.093 (0.612, 1.952) 0.76   
Diabetes, n (%) 16 (20) 26 (22) 0.705 (0.340, 1.462) 0.35   
COPD/asthma, n (%) 17 (21) 20 (17) 1.190 (0.574, 2.470) 0.64   
Neurological disease, n (%) 9 (11) 21 (18) 0.686 (0.296, 1.589) 0.38   
Chronic renal disease, n (%) 11 (14) 19 (16) 0.813 (0.358, 1.846) 0.62   
Liver cirrhosis, n (%) 2 (2) 9 (8) 0.358 (0.075, 1.704) 0.19   
Vasopressor therapy, n (%) 50 (62) 84 (71) 0.628 (0.342, 1.151) 0.13   
Duration of vasopressor therapy, days 4 (2 to 5) 3 (2 to 5) 1.032 (0.918, 1.159) .060   
Cumulative vasopressor dose, mcg 10.5 (3.8, 28.8) 31.0 (11.1, 101.8) 0.992 (0.986, 0.999) 0.02   
Dobutamine therapy, n (%) 39 (48) 55 (47) 0.900 (0.650, 1.246) 0.53   
Cumulative dobutamine dose, mcg 964 (274 to 1978) 1746 (722 to 3378) 1.002 (1.001, 1.009) 0.04   
Duration of MV, days 3 (2 to 5) 3 (2 to 5) 1.052 (0.975, 1.136) 0.19   
CRRT, n (%) 11 (14) 13 (58) 1.491 (0.631, 3.525) 0.36   
Lactate on admission, mEq/L 2.4 (1.6, 3.8) 3.8 (2.1, 6.8) 0.844 (0.758, 0.940) 0.002 0.864 (0.746, 0.999) 0.049
Fluid balance at 48 h, mL 3714 (1867 to 5970) 4197 (2575 to 6729) 1.199 (0.875, 1.342)* 0.53   
CrCl on day 1, mL/min 54 (23 to 92) 33 (11 to 78) 1.002 (0.998, 1.007) 0.32   
  1. Results are expressed as median (IQR) or number (%). *Per liter of fluid balance. CA, cardiac arrest; CPR, cardiopulmonary resuscitation; ROSC, return of spontaneous circulation; VF/VT, ventricular fibrillation/ventricular tachycardia; COPD, chronic obstructive pulmonary disease; IABP, intra-aortic balloon pump counterpulsation; ECMO, extracorporeal membrane oxygenation; MV, mechanical ventilation; CVVH, continuous veno-venous hemofiltration; CrCl, creatinine clearance.